BCL2L14 and B-cell chronic lymphocytic leukemia: In SpiD3-treated venetoclax-resistant CLL cells, the expression of TNFSF10 (TRAIL) and BCL2L14 anti-apoptotic genes was reduced, indicating that SpiD3 can modulate venetoclax-resistant apoptosis mechanisms.